

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1548)**

## **VOLUNTARY ANNOUNCEMENT APPOINTMENT OF DIRECTOR BY LEGEND BIOTECH CORPORATION**

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that, effective 20 January 2026 (the “**Effective Date**”) the board of directors (the “**Legend Board**”) of Legend Biotech Corporation (“**Legend**”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, appointed Mr. Jiange Meng (“**Mr. Robin Meng**”) as a director, with an initial term until Legend’s 2026 annual general meeting of shareholders. Mr. Robin Meng was appointed to replace Dr. Li Zhu who resigned from the Legend Board on the Effective Date.

Mr. Robin Meng has significant experience in senior leadership, finance, and corporate governance in the life sciences and biotechnology sector. He is the chairman and an executive Director of the Company, and has been employed at the Company in various roles since 2010. Prior to joining the Company, Mr. Robin Meng served in finance roles at Quay Magnesium, Saint Gobain, and Schering-Plough China. He holds a Bachelor of Engineering from Changsha University of Science and Technology and a Master of Finance from Queen’s University in Canada.

For details, please refer to the full Form 6-K as published by Legend on 23 January 2026 (New York time) (after trading hours on 23 January 2026 in Hong Kong) on the United States Securities and Exchange Commission’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000117184326000398/0001171843-26-000398-index.html>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**Robin Meng**  
*Chairman and Executive Director*

Hong Kong, 23 January 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*